Clinical importance of serum secreted clusterin in predicting invasive breast cancer and treatment responses

References

• Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–289.
   PubMed Web of Science ®Google Scholar
• Itani N, Grogan N, Mott S, et al. Metastatic presentations of previously treated early-stage breast cancer patients and association with survival. Clin Breast Cancer. 2019;3:S1526-8209:30735–30739. DOI:10.1016/j.clbc.2019.11.004
   PubMed Web of Science ®Google Scholar
• Skuli SJ, Sheng JY, Bantug ET, et al. Survivorship care visits in a high-risk population of breast cancer survivors. Breast Cancer Res Treat. 2019;173(3):701–708.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-y survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. .
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. ESMO guidelines committee. early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1674.
   PubMed Web of Science ®Google Scholar
• Ikubo A, Matsufuji S, Morifuji Y, et al. clinical features, prognosis, diagnostic approaches and treatment of multiple primary malignancies in the digestive system. Anticancer Res. 2019;39(12):6863–6870.
   PubMed Web of Science ®Google Scholar
• Burton C, Ma Y. Current trends in cancer biomarker discovery using urinary metabolomics: achievements and new challenges. Curr Med Chem. 2019;26(1):5–28.
   PubMed Web of Science ®Google Scholar
• Ryška A. Molecular pathology in real time. Cancer Metastasis Rev. 2016;35(1):129–140.
   PubMed Web of Science ®Google Scholar
• Lipton A, Leitzel K, Ali SM, et al. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer. 2011;117(21):5013–5020.
   PubMed Web of Science ®Google Scholar
• Kjaer IM, Bechmann T, Brandslund I, et al. Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review. Clin Chem Lab Med. 2018;56(5):688–701.
   PubMed Web of Science ®Google Scholar
• Finn RS, Gagnon R, Di Leo A, et al. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009;27(33):5552–5558.
   PubMed Web of Science ®Google Scholar
• Joyce DP, Kerin MJ, Dwyer RM. Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer.Int. J Cancer. 2016;139(7):1443–1448.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Walsh S, McDermott EW, et al. Biomarkers in breast cancer: where are we and where are we going? Adv Clin Chem. 2015;71:1–23.
   PubMed Web of Science ®Google Scholar
• Rizzi F, Coletta M, Bettuzzi S. Chapter 2: clusterin (CLU): from one gene and two transcripts to many proteins. Adv Cancer Res. 2009;104:9–23.
   PubMed Web of Science ®Google Scholar
• Moretti RM, Montagnani Marelli M, Mai S, et al. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res. 2007;67(21):10325–10333.
   PubMed Web of Science ®Google Scholar
• Xiu P, Xu Z, Liu F, et al. Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway. Dig Dis Sci. 2014;59(8):1798–1809.
   PubMed Web of Science ®Google Scholar
• Shepherd CE, Affleck AJ, Bahar AY, et al. Intracellular and secreted forms of clusterin are elevated early in Alzheimer’s disease and associate with both Aβ and tau pathology. Neurobiol Aging. 2019;19: 30389–30386.
   Google Scholar
• Kim N, Choi WS. Proapoptotic role of nuclear clusterin in brain. Anat Cell Biol. 2011;44(3):169–175.
   PubMedGoogle Scholar
• Pucci S, Polidoro C, Joubert A, et al. Ku70, ku80, and sclusterin: a cluster of predicting factors for response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2017;97(2):381–388.
   PubMed Web of Science ®Google Scholar
• Peng M, Deng J, Zhou S, et al. The role of clusterin in cancer metastasis. Cancer Manag Res. 2019;11:2405–2414.
   PubMed Web of Science ®Google Scholar
• Henderson-Jackson EB, Nasir A, Chen DT, et al. cytoplasmic clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage. Pancreas. 2013;42(6):967–970.
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res. 2010;16(4):1088–1093.
   PubMed Web of Science ®Google Scholar
• Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer. 2009;19(8):1342–1346.
   PubMed Web of Science ®Google Scholar
• Pins MR, Fiadjoe JE, Korley F, et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis. 2004;7(3):243–248.
   PubMed Web of Science ®Google Scholar
• Pucci S, Bonanno E, Sesti F, et al. Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol. 2009;104(11):2807–2815.
   PubMed Web of Science ®Google Scholar
• Hazzaa SM, Elashry OM, Afifi IK. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res. 2010;16(1):101–109.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Piñeiro AM, García-Lorenzo A, Blanco-Prieto S, et al. Secreted clusterin in colon tumor cell models and its potential as diagnostic marker for colorectal cancer. Cancer Invest. 2012;30(1):72–78.
   PubMed Web of Science ®Google Scholar
• Ma J, Gao W, Gao J. sCLU as prognostic biomarker and therapeutic target in osteosarcoma. Bioengineered. 2019;10(1):229–239.
   PubMed Web of Science ®Google Scholar
• Niu ZH, Wang Y, Chun B, et al. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. Eur Rev Med Pharmacol Sci. 2013;17(10):1337–1344.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Zhao H, et al. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J Chemother. 2012;24(6):348–357.
   PubMed Web of Science ®Google Scholar
• Niu Z, Li X, Hu B, et al. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Acta Biochim Biophys Sin. 2012;44(12):991–998.
   Google Scholar
• Janiszewska E, EM K. Could the glycosylation analysis of seminal plasma clusterin become a novel male infertility biomarker? Mol Reprod Dev. 2020;87(5):515–524.
   PubMed Web of Science ®Google Scholar
• Guo J, Guan Q, Liu X, et al. Relationship of clusterin with renal inflammation and fibrosis after the recovery phase of ischemia-reperfusion injury. BMC Nephrol. 2016;17(1):133.
   PubMedGoogle Scholar
• Zhang Y, Zhang Y, Xiao Y, et al. Expression of Clusterin suppresses Cr(VI)-induced premature senescence through activation of PI3K/AKT pathway. Ecotoxicol Environ Saf. 2019;183:109465.
   PubMed Web of Science ®Google Scholar
• Tellez T, Garcia-Aranda M, Redondo M. The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target. Curr Med Chem. 2016;23(38):4297–4308.
   PubMed Web of Science ®Google Scholar
• Udomsinprasert W, Poovorawan Y, Chongsrisawat V, et al. Decreased circulating clusterin reflects severe liver complications after hepatoportoenterostomy of biliary atresia. Sci Rep. 2020;10(1):19736.
   PubMed Web of Science ®Google Scholar
• Pucci S, Bonanno E, Sesti F, et al. Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol. 2009;104(11):2807–2815.
   PubMed Web of Science ®Google Scholar
• Kimura A, Sogawa K, Satoh M, et al. The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma. Int J Proteomics. 2012;2012:623190.
   PubMedGoogle Scholar
• Čapoun O, Soukup V, Kalousová M, et al. Diagnostic importance of selected protein serum markers in the primary diagnostics of prostate cancer. Urol Int. 2015;95(4):429–435.
   PubMed Web of Science ®Google Scholar
• Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res. 2009;105:77–92.
   PubMed Web of Science ®Google Scholar
• Hoeller C, Pratscher B, Thallinger C, et al. Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005;124(6):1300–1307.
   PubMed Web of Science ®Google Scholar
• Chi KN, Chin JL, Winquist E, et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.J. Urol. 2008;180(2):565–570.
   Web of Science ®Google Scholar